Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, University Utrecht, Huispost nr. STR 6.131, P.O. Box 85500, 3508 GA, Utrecht, the Netherlands.
Department of Medical Microbiology, University Medical Center Utrecht, University Utrecht, Utrecht, the Netherlands.
Eur J Clin Microbiol Infect Dis. 2020 Feb;39(2):265-271. doi: 10.1007/s10096-019-03718-5. Epub 2019 Nov 6.
The objective of this study was to determine the value of using SuperPolymyxin™ selective medium (ELITech Group, Puteaux, France) in addition to conventional non-selective inoculation methods in the detection of acquired colistin resistance in a Dutch intensive care unit (ICU) that routinely uses selective decontamination of the digestive tract (SDD). We performed a cross-sectional study with prospective data collection in a tertiary-care ICU. All consecutive surveillance rectal swabs of ICU-patients receiving SDD were included and cultured in an observer-blinded approach using (1) a conventional culture method using non-selective media and (2) SuperPolymyxin™ selective medium. MIC values for colistin of non-intrinsically colistin-resistant Gram-negative isolates were determined with broth microdilution (BMD) using Sensititre™ and colistin resistance was confirmed using BMD according to EUCAST guidelines. One thousand one hundred five rectal swabs of 428 unique ICU-patients were inoculated using both culture methods, yielding 346 and 84 Gram-negative isolates for BMD testing with the conventional method and SuperPolymyxin™ medium, of which 308 and 80 underwent BMD, respectively. The number of identified rectal carriers of isolates with acquired colistin resistance was 3 (0.7%) for the conventional method, 4 (0.9%) for SuperPolymyxin™, and 5 (1.2%) for both methods combined. The number of isolates with acquired colistin resistance was 4 (1.0%) for the conventional method, 8 (2.1%) for SuperPolymyxin™ and 9 (2.3%) for both methods combined. In a surveillance setting of low prevalence of acquired colistin resistance in patients that receive SDD in a Dutch tertiary-care ICU, SuperPolymyxin™ had a higher diagnostic yield than conventional inoculation methods, but the combination of both had the highest diagnostic yield.
本研究旨在确定在荷兰重症监护病房(ICU)中使用选择性去污(SDD)常规情况下,使用 SuperPolymyxin™ 选择性培养基(ELITech Group,法国 Puteaux)除了传统的非选择性接种方法之外,检测获得性多粘菌素耐药性的价值。我们进行了一项横断面研究,前瞻性收集了三级护理 ICU 的数据。所有接受 SDD 的 ICU 患者的连续监测直肠拭子均包含在研究中,并采用盲法观察者方法进行培养,使用(1)传统的非选择性培养基培养方法和(2)SuperPolymyxin™ 选择性培养基。采用 Sensititre™肉汤微量稀释法(BMD)测定非固有耐药的革兰氏阴性分离株的多粘菌素 MIC 值,并根据 EUCAST 指南使用 BMD 法确认多粘菌素耐药性。使用两种培养方法对 428 名 ICU 患者的 1105 份直肠拭子进行接种,共获得 346 株和 84 株革兰氏阴性分离株进行 BMD 检测,分别采用传统方法和 SuperPolymyxin™ 培养基,其中 308 株和 80 株分别进行 BMD。通过传统方法鉴定出 3 株(0.7%)直肠携带获得性多粘菌素耐药的分离株,SuperPolymyxin™ 为 4 株(0.9%),两种方法均为 5 株(1.2%)。传统方法鉴定出 4 株(1.0%)分离株具有获得性多粘菌素耐药性,SuperPolymyxin™ 为 8 株(2.1%),两种方法均为 9 株(2.3%)。在荷兰三级护理 ICU 中接受 SDD 的患者中,获得性多粘菌素耐药性的低流行率监测环境下,SuperPolymyxin™ 的诊断效果优于传统接种方法,但两者的联合应用具有最高的诊断效果。